Big cash inflow last quarter, market rallied slightly and then fell back to support recognising it was cash coming in that was largely going to go back out again.
Big cash outflow this quarter and the expected drop in share price, but I expect the market to again revert back to support.
Next quarter is likely going to include yet another large IC progress payment, which will inevitably largely go out again. Richard’s said it many times, large cash inflows and outflows are to expected with IC. Net cash inflows over the course of the project is the key.
SPS revenue guidance of US$35-US$50m maintained, which means they expect a ramp up in sales in the next few quarters.
let’s wait and see, but keep in mind the cash on hand doesn’t include the restricted cash which will be released over the next 18months.
don’t see a need for a cap raise given ample debt and IC inflows due, but the exception would be if sales do ramp up significantly and they need cash to scale up, which would mean SP would be much higher than where it is now.
goodluck all
- Forums
- ASX - By Stock
- FLC
- Ann: Fluence Business Update for Q1 2021
Ann: Fluence Business Update for Q1 2021, page-12
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FLC (ASX) to my watchlist
|
|||||
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $108.0M |
Open | High | Low | Value | Volume |
10.0¢ | 10.0¢ | 9.5¢ | $141.4K | 1.419M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 9.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 100000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.097 |
1 | 100000 | 0.095 |
1 | 5799 | 0.092 |
2 | 147490 | 0.090 |
1 | 1176 | 0.085 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 100000 | 1 |
0.110 | 185514 | 3 |
0.115 | 115012 | 3 |
0.120 | 260053 | 3 |
0.130 | 75364 | 3 |
Last trade - 15.59pm 13/08/2024 (20 minute delay) ? |
Featured News
FLC (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online